San Diego
,
California
9 - 12 December 2023
American Society of Hematology (ASH) 2023
Presentation schedule and materials
Saturday, 09 December 2023
09:30
- 11:00
Pacific Standard Time
30
ORAL PRESENTATION
Surgical procedures and hemostatic outcome in patients with hemophilia receiving concizumab prophylaxis during the phase 3 explorer7 and explorer8 trials
Chan AKC1; Barnes C2; Mathias M3; Linari S4; Lopez Jaime F5; Poulsen LH6; Bovet J7; Odgaard Jensen J7; Matsushita T8
16:00
- 17:30
Pacific Standard Time
284
ORAL PRESENTATION
The effect of concizumab prophylaxis on target joints, resolution and joint bleeds in patients with hemophilia A or B with or without inhibitors in phase 3 clinical trials
Castaman G1; Abraham A2; Angchaisuksiri P3; Villarreal Martinez L4; Nogami K5; Sathar J6; Shen C7; Thaung Zaw JJ7; Young G8
17:30
- 19:30
Pacific Standard Time
2367
POSTER
Assessing treatment burden in pediatric hemophilia: validation of the observer-reported child hemophilia treatment experience measure (Child Hemo-TEM)
Meryl Brod, PhD1; Donald M. Bushnell, MA2; Anne Kirstine Busk, MSc3; Jesper Skov Neergaard, PhD3
Sunday, 10 December 2023
12:00
- 13:30
Pacific Standard Time
508
ORAL PRESENTATION
Treatment related clinical and humanistic unmet needs in hemophilia A without inhibitors
Allison P Wheeler1; John Waller2; Sanket Shah3; Mohd Nawi Wahid2; Jennifer Dusendang4; Amy Shapiro5
18:00
- 20:00
Pacific Standard Time
3755
POSTER
Understanding treatment burden in pediatric hemophilia: development of the child hemophilia treatment experience measure (Child Hemo-TEM)
Meryl Brod, PhD1; Anne Kirstine Busk, MSc2; Jesper Skov Neergaard, PhD2
18:00
- 20:00
Pacific Standard Time
2609
POSTER
Efficacy and safety of concizumab prophylaxis in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study
Astermark J1; Apte S2; Joo Lyu C3; Rhode Høgh Nielsen A4; Saulyte Trakymiene S5; Thaung Zaw JJ6; Tran H6; Windyga J7; Eichler H8
18:00
- 20:00
Pacific Standard Time
3251
POSTER
FORTITUDE: A phase 2 open-label study in progress to evaluate etavopivat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes
Mikkael A. Sekeres1; Uwe Platzbecker2; Rasmus Heje Thomsen3; Sam Wilson4; Anne S. Renteria4; Pierre Fenaux5
18:00
- 20:00
Pacific Standard Time
2498
POSTER
Motivators and barriers for people with sickle cell disease participating in clinical trials: global findings from the LISTEN survey
John James1; Biree Andemariam2; Johnny Mahlangu3; Raffaella Colombatti4; John Waller5; Samar Al-Behaisi5; Adam Wufsus6; Gareth Morrell7; Cassandra Trimnell8
Keywords